Consolidation with autologous stem cell transplantation in first remission is safe and effective in AML patients above 65 years.
The outcome of AML patients ≥65 years remains disappointing. Current post-induction strategies for elderly AML patients fit for intensive treatment involve additional cycles of chemotherapy or allogeneic transplantation. Consolidation with autologous transplantation (ASCT) is poorly studied in these patients. In this single-center retrospective analysis, we determined survival rates of AML patients ≥65 years undergoing busulfan/cyclophosphamide conditioning before ASCT in first remission between 2007 and 2015. We found elderly AML patients with ASCT to have longer progression-free survival (PFS; 16.3 vs. 5.1 months, P=0.0166) and overall survival (OS; n.r. vs. 8.2 months; P=0.0255) than elderly AML patients without ASCT consolidation. In addition, elderly AML patients undergoing ASCT had comparable PFS (P=0.9462) and OS (P=0.7867) as AML patients below 65 years receiving ASCT consolidation in CR1. Our data suggest that ASCT is an option in elderly fit AML patients who appear to benefit from autologous consolidation similarly to younger AML patients.
['Heini|Alexander D|AD|', 'Berger|Martin D|MD|', 'Seipel|Katja|K|', 'Taleghani|Behrouz Mansouri|BM|', 'Baerlocher|Gabriela M|GM|', 'Leibundgut|Kurt|K|', 'Banz|Yara|Y|', 'Novak|Urban|U|', 'Pabst|Thomas|T|']
D000367:Age Factors D000368:Aged D000369:Aged, 80 and over D002066:Busulfan D003520:Cyclophosphamide D005260:Female D018380:Hematopoietic Stem Cell Transplantation D006801:Humans D015470:Leukemia, Myeloid, Acute D008297:Male D012074:Remission Induction D012189:Retrospective Studies D015996:Survival Rate D019172:Transplantation Conditioning D014182:Transplantation, Autologous D016896:Treatment Outcome
Autologous Transplant AML Elderly Survival